Related Experiment Video
Updated: Jan 21, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate
Mark P Labrecque1, Ilsa M Coleman2,3, Lisha G Brown1
1Department of Urology, University of Washington, Seattle, Washington, USA.
Abstract:
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with diverse drivers of disease progression and mechanisms of therapeutic resistance. We conducted deep phenotypic characterization of CRPC metastases and patient-derived xenograft (PDX) lines using whole genome RNA sequencing, gene set enrichment analysis and immunohistochemistry. Our analyses revealed five mCRPC phenotypes based on the expression of well-characterized androgen receptor (AR) or neuroendocrine (NE) genes: (i) AR-high tumors (ARPC), (ii) AR-low tumors (ARLPC), (iii) amphicrine tumors composed of cells co-expressing AR and NE genes (AMPC), (iv) double-negative tumors (i.e. AR-/NE-; DNPC) and (v) tumors with small cell or NE gene expression without AR activity (SCNPC). RE1-silencing transcription factor (REST) activity, which suppresses NE gene expression, was lost in AMPC and SCNPC PDX models. However, knockdown of REST in cell lines revealed that attenuated REST activity drives the AMPC phenotype but is not sufficient for SCNPC conversion. We also identified a subtype of DNPC tumors with squamous differentiation and generated an encompassing 26-gene transcriptional signature that distinguished the five mCRPC phenotypes. Together, our data highlight the central role of AR and REST in classifying treatment-resistant mCRPC phenotypes. These molecular classifications could potentially guide future therapeutic studies and clinical trial design.
Insights
Metastatic castration-resistant prostate cancer (mCRPC) exhibits five distinct phenotypes based on androgen receptor (AR) and neuroendocrine (NE) gene expression. Understanding these AR and RE1-silencing transcription factor (REST) driven classifications is key for future prostate cancer treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) is a complex disease characterized by heterogeneity in disease progression and therapeutic resistance.
- Understanding the molecular drivers of mCRPC is crucial for developing effective treatment strategies.
Purpose of the Study:
- To deeply phenotype mCRPC metastases and patient-derived xenograft (PDX) lines.
- To identify distinct molecular subtypes of mCRPC based on gene expression profiles.
- To elucidate the roles of androgen receptor (AR) and RE1-silencing transcription factor (REST) in mCRPC phenotypes.
Main Methods:
- Whole genome RNA sequencing of mCRPC metastases and PDX lines.
- Gene set enrichment analysis to identify molecular pathways.
- Immunohistochemistry to validate protein expression.
- REST knockdown experiments in cell lines.
Main Results:
- Five mCRPC phenotypes were identified: AR-high (ARPC), AR-low (ARLPC), amphicrine (AMPC), double-negative (DNPC), and small cell/neuroendocrine (SCNPC).
- Loss of RE1-silencing transcription factor (REST) activity was observed in AMPC and SCNPC PDX models.
- Attenuated REST activity drives the AMPC phenotype, but is insufficient for SCNPC conversion.
- A 26-gene signature was developed to distinguish the five mCRPC phenotypes, including a squamous differentiation subtype within DNPC.
Conclusions:
- Androgen receptor (AR) and RE1-silencing transcription factor (REST) play central roles in classifying treatment-resistant mCRPC phenotypes.
- Molecular classification of mCRPC subtypes can potentially guide future therapeutic studies and clinical trial design.
- Identification of distinct mCRPC phenotypes offers new avenues for targeted therapies.
Related Concept Videos
Treatment Resistant Cancers
Stratified Sampling Method
To choose a stratified sample, divide the population into groups called strata and then take a...
Classification of Epithelial Tissues: Stratified Epithelium
Diversity of Archaea I
Diversity of Archaea II
Diversity of Protists I

